- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FRα Biomarker Testing in Patients With Ovarian Cancer
A panelist discusses how folate receptor alpha (FRα) expression testing plays a crucial role in determining eligibility for mirvetuximab soravtansine (an antibody-drug conjugate therapy), emphasizing the importance of comprehensive biomarker testing at diagnosis rather than piecemeal testing.
EP: 1.The Role of Guidelines on Molecular Testing in Ovarian Cancer
EP: 2.FRα Biomarker Testing in Patients With Ovarian Cancer
EP: 3.Emerging Molecular Biomarkers in Ovarian Cancer
EP: 4.Comprehensive Molecular Testing in Patients With Ovarian Cancer
EP: 5.The Impact of Tumor Heterogeneity in Ovarian Cancer
EP: 6.Improving Clinician Awareness and Adoption of Molecular Testing
EP: 7.Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer
EP: 8.The Role of Novel Targeted Therapies
EP: 9.The Use of PARP Inhibitors in Ovarian Cancer
EP: 10.Earlier Introduction of Antibody-Drug Conjugates
EP: 11.Approaching Treatment Sequencing In Heavily Pretreated Patients
EP: 12.Single-Agent Vs Combination Regimens
EP: 13.The Potential Impact of Investigational Therapies
EP: 14.Learnings From Key Clinical Trials in Ovarian Cancer
Video content above is prompted by the following:
Role of Folate Receptor Alpha Testing
Mirvetuximab soravtansine, an antibody-drug conjugate targeting FRα, represents the newest approved therapy in ovarian cancer. Testing considerations include the following:
- Immunohistochemistry evaluation assesses the percentage of positive cells and staining intensity.
- Optimal response predictors are cells with 2+ or greater staining intensity in 75% or more of tumor cells.
- Testing should be integrated into comprehensive molecular profiling at diagnosis.
- There is minimal spatial or temporal heterogeneity in ovarian cancer biomarkers, making initial testing generally reliable throughout treatment.
The NCCN recommends universal FRα testing as part of comprehensive biomarker assessment, which has shifted from individual tests to comprehensive panels performed at diagnosis.
In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel
June 24th 2025In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.
Read More
